CV Impact of Immune Checkpoint Inhibitor Cardiotoxicity

Watch the full video on Radcliffe Cardiology here:

The use of immune checkpoint inhibitors (ICI) to treat cancer patients can impact the cardiovascular system (CV) and can lead to cardiac injury/disfunction and the development of myocarditis.

Our latest discussion features Dr Tomas Neilan (Massachusetts General Hospital, Boston, US) who presents information on the use of ICI therapy to care for patients with cancer and considers the potential CV impact. Dr Arjun Ghosh moderates the discussion.

Dr Neilan presents data on patient outcomes, fatality rates and highlights current evidence to showcase how immune therapy leads to an increase in atherosclerosis and pericardial disease. He also highlights how ICI will drive the future of cancer care and looks forward to the many phase 1-3 studies that are underway.

Together they discuss if physicians should be screening patients for checkpoint inhibitor therapy and the challenges around this and consider how often physicians should monitor patients for increased troponin levels, post treatment of checkpoint inhibition?

This content is intended for healthcare professionals only.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.